Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros











Intervalo de año de publicación
1.
Biol Res ; 54(1): 13, 2021 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-33879265

RESUMEN

BACKGROUND: Helicobacter pylori is detected by pathogen recognition receptors including toll-like receptors (TLR) and nucleotide-binding oligomerization domain (NOD)-like receptors, eliciting an innate immune response against this bacteria. The aim of this study was to assess if polymorphisms of TLR2, TLR4, TLR5, NOD1 and NOD2 genes are associated with gastric cancer, in particular in individuals infected with H. pylori. RESULTS: A case-control study of 297 gastric cancer patients and 300 controls was performed to assess the association of 17 polymorphisms. Analyses performed under the allele model did not find association with gastric cancer. However, NOD1 rs2075820 (p.E266K) showed association with intestinal-type gastric cancer among H. pylori infected subjects (OR = 2.69, 95% CI 1.41-5.13, p = 0.0026). The association was not statistically significant in diffuse-type gastric cancer cases (OR = 1.26, 95% CI 0.63-2.52, p = 0.51). When the analyses were performed in patients carrying H. pylori strains harboring the cag pathogenicity island (cagPAI), we noticed significant association with NOD1 rs2075820 (OR = 4.90, 95% CI 1.80-3.36, p = 0.0019), in particular for intestinal-type gastric cancer cases (OR = 7.16, 95% CI 2.40-21.33, p = 4.1 × 10- 4) but not among diffuse-type gastric cancer cases (OR = 3.39, 95% CI 1.13-0.10, p = 0.03). CONCLUSIONS: NOD1 rs2075820 increases the risk of intestinal-type gastric cancer among individuals infected with H. pylori, particularly in those harboring the cagPAI.


Asunto(s)
Infecciones por Helicobacter , Proteína Adaptadora de Señalización NOD1/genética , Neoplasias Gástricas , Estudios de Casos y Controles , Islas Genómicas , Infecciones por Helicobacter/genética , Helicobacter pylori , Humanos , Neoplasias Gástricas/genética
2.
Biol. Res ; 54: 13-13, 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1505806

RESUMEN

BACKGROUND: Helicobacter pylori is detected by pathogen recognition receptors including toll-like receptors (TLR) and nucleotide-binding oligomerization domain (NOD)-like receptors, eliciting an innate immune response against this bacteria. The aim of this study was to assess if polymorphisms of TLR2, TLR4, TLR5, NOD1 and NOD2 genes are associated with gastric cancer, in particular in individuals infected with H. pylori. RESULTS: A case-control study of 297 gastric cancer patients and 300 controls was performed to assess the association of 17 polymorphisms. Analyses performed under the allele model did not find association with gastric cancer. However, NOD1 rs2075820 (p.E266K) showed association with intestinal-type gastric cancer among H. pylori infected subjects (OR = 2.69, 95% CI 1.41-5.13, p = 0.0026). The association was not statistically significant in diffuse-type gastric cancer cases (OR = 1.26, 95% CI 0.63-2.52, p = 0.51). When the analyses were performed in patients carrying H. pylori strains harboring the cag pathogenicity island (cagPAI), we noticed significant association with NOD1 rs2075820 (OR = 4.90, 95% CI 1.80-3.36, p = 0.0019), in particular for intestinal-type gastric cancer cases (OR = 7.16, 95% CI 2.40-21.33, p = 4.1 × 10- 4) but not among diffuse-type gastric cancer cases (OR = 3.39, 95% CI 1.13-0.10, p = 0.03). CONCLUSIONS: NOD1 rs2075820 increases the risk of intestinal-type gastric cancer among individuals infected with H. pylori, particularly in those harboring the cagPAI.


Asunto(s)
Humanos , Neoplasias Gástricas/genética , Infecciones por Helicobacter/genética , Proteína Adaptadora de Señalización NOD1/genética , Estudios de Casos y Controles , Helicobacter pylori , Islas Genómicas
3.
Mol Biol Rep ; 47(11): 9239-9243, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33128686

RESUMEN

Genetic variants are considered risk factors for gastric cancer. To date, 61 polymorphisms have been identified as associated with this disease. The aim of the present study was to analyze the association of some of those polymorphisms with GC in Chile. We performed a case-control study including 310 gastric cancer cases and 311 controls to assess the association of 36 single-nucleotide polymorphisms genotyped by Global Screening Array (GSA). Three polymorphisms was significantly associated: PSCA rs2294008 (allele model, OR = 1.49, 95%CI 1.17-1.88, P = 1.08 × 10-3), IL-4 rs2243250 (allele model, OR = 1.28, 95%CI 1.01-1.62, P = 0.04), and MUC1 rs4072037 (allele model, OR = 0.78, 95%CI 0.61-0.99, P = 0.04).PSCA rs2294008, IL-4 rs2243250 and MUC1 rs4072037 are associated with gastric cancer in Chile. It suggests that those polymorphisms could be used as biomarkers to assess the genetic risk for this cancer outside of the previously studied populations, not only for East Asians and Caucasians populations.


Asunto(s)
Antígenos de Neoplasias/genética , Predisposición Genética a la Enfermedad/genética , Interleucina-4/genética , Mucina-1/genética , Proteínas de Neoplasias/genética , Polimorfismo de Nucleótido Simple , Neoplasias Gástricas/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Estudios de Casos y Controles , Chile , Femenino , Proteínas Ligadas a GPI/genética , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Adulto Joven
4.
Anticancer Res ; 38(10): 5703-5708, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30275190

RESUMEN

BACKGROUND/AIM: Inflammation is a key process in gastric carcinogenesis. Cytokines are mediators of inflammation and are involved in metastasis and tumorigenicity. We previously assessed the role of cytokine gene polymorphisms in gastric cancer risk in Chile. In the present study, we aimed to analyze whether these polymorphisms are associated with overall survival (OS) in gastric cancer (GC) patients. PATIENTS AND METHODS: A total of 153 individuals with GC diagnosis were followed-up for at least 2 years. Hazard ratios (HR) were estimated from Cox regression models using SNPs as predictor variables. The following SNPs were genotyped for study using a TaqMan assay: rs16944 (IL1B -511C>T); rs4073 (IL8 -251 T>A); rs2275913 (IL-17 -197G>A); rs1800872 (IL10 -592 C>A); rs1800896 (IL10 -1082A>G); rs28372698 (IL32). RESULTS: Interleukin-8 rs4073 (IL-8 -251T>A) showed association with OS under the dominant model (TA + AA) only when adjusted by clinicopathological variables (HR=1.64, 95%CI=1.05-2.55, p=0.030, q-value=0.18), but not with the univariate model (HR=1.51, 95%CI=0.98-2.31, p=0.062, q-value=0.37). No significant differences were observed after adjusting for population stratification (PC1 and PC2 from Principal Component Analysis using genotypes from Infinium Global Screening Array). After stratification by clinicopathological variables, the association with shorter overall survival was higher among patients with diffuse-type tumors (HR=2.24, 95%CI=1.16-4.45) and patients with tumor size >5 cm (HR=1.79, 95%CI=1.08-2.97). CONCLUSION: These results suggest a role of IL-8 rs4073 in cancer prognosis. Its use as a prognostic marker of GC survival warrants further investigation.


Asunto(s)
Adenocarcinoma/genética , Interleucina-8/genética , Polimorfismo de Nucleótido Simple , Neoplasias Gástricas/genética , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Biomarcadores de Tumor , Humanos , Pronóstico , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía , Tasa de Supervivencia
5.
Anticancer Res ; 38(7): 3871-3877, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29970507

RESUMEN

BACKGROUND/AIM: Epithelial-mesenchymal transition (EMT) program has been linked as a driver of metastatic dissemination by conferring migratory and invasive capacity to cancer cells. Gastric cancer (GC) patients with tumors expressing altered levels of EMT markers have low survival. This study aimed to assess if polymorphisms of CDH1, TWIST1, SNAIL2, ZEB1 and ZEB2 genes are associated with survival in GC patients. PATIENTS AND METHODS: A total of 153 individuals with diagnosis of GC were recruited in Santiago, Chile. All patients were genotyped using Infinium Global Screening Array (GSA). Twenty Tag SNPs of the studied genes were retrieved. RESULTS: Three SNPs were associated with survival: rs2526614 (TWIST1) (genotype CA + AA, adjusted HR=0.58, 95%CI=0.37-0.93), rs6953766 (TWIST1) (genotype GG, crude HR=2.02, 95%CI=1.06-3.82, adjusted HR=2.14, 95%CI=1.07-4.25), and rs431073 (ZEB1) (genotype AC + CC, crude HR=1.62, 95%CI=1.01-2.59, adjusted HR=1.96, 95%CI=1.18-3.25). CONCLUSION: To the best of our knowledge, this is the first study proposing a role of these SNPs in cancer prognosis. Their use as prognostic markers of GC survival warrants further investigation.


Asunto(s)
Proteínas Nucleares/genética , Polimorfismo de Nucleótido Simple , Neoplasias Gástricas/patología , Proteína 1 Relacionada con Twist/genética , Homeobox 1 de Unión a la E-Box con Dedos de Zinc/genética , Adulto , Anciano , Anciano de 80 o más Años , Transición Epitelial-Mesenquimal/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias Gástricas/genética , Tasa de Supervivencia
6.
Genes (Basel) ; 10(1)2018 Dec 28.
Artículo en Inglés | MEDLINE | ID: mdl-30597917

RESUMEN

The RAS/RAF/MEK/ERK pathway regulates certain cellular functions, including cell proliferation, differentiation, survival, and apoptosis. Dysregulation of this pathway leads to the occurrence and progression of cancers mainly by somatic mutations. This study aimed to assess if polymorphisms of the RAS/RAF/MEK/ERK pathway are associated with gastric cancer. A case-control study of 242 gastric cancer patients and 242 controls was performed to assess the association of 27 single nucleotide polymorphisms (SNPs) in the RAS/RAF/MEK/ERK pathway genes with gastric cancer. Analyses performed under the additive model (allele) showed four significantly associated SNPs: RAF1 rs3729931 (Odds ratio (OR) = 1.54, 95%, confidence interval (CI): 1.20⁻1.98, p-value = 7.95 × 10-4), HRAS rs45604736 (OR = 1.60, 95% CI: 1.16⁻2.22, p-value = 4.68 × 10-3), MAPK1 rs2283792 (OR = 1.45, 95% CI: 1.12⁻1.87, p-value = 4.91 × 10-3), and MAPK1 rs9610417 (OR = 0.60, 95% CI: 0.42⁻0.87, p-value = 6.64 × 10-3). Functional annotation suggested that those variants or their proxy variants may have a functional effect. In conclusion, this study suggests that RAF1 rs3729931, HRAS rs45604736, MAPK1 rs2283792, and MAPK1 rs9610417 are associated with gastric cancer.

7.
Rev. chil. cir ; 70(1): 66-69, 2018. ilus
Artículo en Español | LILACS | ID: biblio-899658

RESUMEN

Resumen Introducción El melanoma maligno primario de esófago es un tumor raro y muy agresivo. De manejo controversial, el tratamiento quirúrgico es el que predomina en enfermedad localizada. Caso clínico Presentamos el caso de una mujer joven con melanoma maligno primario de esófago de presentación atípica y su manejo quirúrgico utilizando la técnica de Akiyama.


Introduction The Primary Malignant Melanoma of Esophagus is an uncommon and very agressive tumor. With controversial management, it predominates the surgical treatment in localized disease. Clinical case We present the case of a young women with Primary Malignant Melanoma of Esophagus with atypical presentation and its surgical management using the Akiyama technique.


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Neoplasias Esofágicas/cirugía , Esofagectomía , Melanoma/cirugía , Neoplasias Esofágicas/diagnóstico , Endoscopía del Sistema Digestivo , Tomografía Computarizada por Tomografía de Emisión de Positrones , Escisión del Ganglio Linfático , Melanoma/diagnóstico
8.
Anticancer Res ; 34(7): 3523-30, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24982364

RESUMEN

AIM: To assess the role of pro- and anti-inflammatory polymorphisms in gastric cancer susceptibility. PATIENTS AND METHODS: We genotyped 12 polymorphisms in eight cytokine genes (Interleukin-1ß -IL1B-, IL8, IL17A, IL17F, IL32, tumor necrosis factor-α -TNF-, IL1RN, IL10) in a case-control study of 147 patients with gastric cancer and 172 controls. RESULTS: Single polymorphism analysis revealed an association between the IL10 -592C>A single nucleotide polymorphism and cases with moderately- or well-differentiated tumors [AA vs. GG, odds ratio (OR)=3.01; 95% confidence interval (CI)=1.08-8.50]. We further analyzed gene-gene interactions using a combined attribute network implemented in multifactor dimensionality reduction software. The analysis revealed an interaction between IL8 -251A>T and IL32 rs28372698 SNPs among cases with moderately- or well-differentiated tumors. Homozygosity for both IL8 -251T and IL32 T alleles increases the odds for developing gastric cancer up to 2.63-fold (OR=2.63; 95% CI=1.15-6.03). This association was higher compared to the homozygosity for the IL8-251 T allele alone (OR=1.11; 95% CI=0.51-2.43) or the IL32 T allele alone (OR=1.21; 95% CI=0.54-2.72). CONCLUSION: These findings suggest that IL10 -592C>A increases the odds for developing gastric cancer. An interaction between IL8 -251A>T and IL32 rs28372698 SNPs is also proposed.


Asunto(s)
Citocinas/genética , Neoplasias Gástricas/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Estudios de Casos y Controles , Chile , Femenino , Predisposición Genética a la Enfermedad , Humanos , Interleucinas/genética , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Neoplasias Gástricas/inmunología , Factor de Necrosis Tumoral alfa/genética
9.
Rev. méd. Chile ; 138(9): 1135-1139, sept. 2010. ilus
Artículo en Español | LILACS | ID: lil-572020

RESUMEN

Peliosis hepatis is a rare vascular condition of the liver characterized by the presence of cystic blood-fi lled cavities distributed randomly throughout the liver parenchyma. We report a 46 year old female, with dyspepsia. An abdominal Doppler ultrasound showed a hyper vascularized solid liver nodule of 5 cm diameter. Magnetic resonance imaging and CT scan showed the same hyper vascularized nodule. With the possible diagnoses of primary hepatocellular carcinoma or focal nodular hyperplasia, the patient was subjected to an excision of hepatic segment VI, where the nodule was located. The pathological diagnosis of the surgical piece was a peliosis hepatis.


Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Peliosis Hepática/diagnóstico , Diagnóstico Diferencial , Hiperplasia Nodular Focal/diagnóstico , Neoplasias Hepáticas/diagnóstico , Imagen por Resonancia Magnética , Tomografía Computarizada por Rayos X , Ultrasonografía Doppler en Color
10.
Rev Med Chil ; 138(9): 1135-9, 2010 Sep.
Artículo en Español | MEDLINE | ID: mdl-21249282

RESUMEN

Peliosis hepatis is a rare vascular condition of the liver characterized by the presence of cystic blood-fi lled cavities distributed randomly throughout the liver parenchyma. We report a 46 year old female, with dyspepsia. An abdominal Doppler ultrasound showed a hyper vascularized solid liver nodule of 5 cm diameter. Magnetic resonance imaging and CT scan showed the same hyper vascularized nodule. With the possible diagnoses of primary hepatocellular carcinoma or focal nodular hyperplasia, the patient was subjected to an excision of hepatic segment VI, where the nodule was located. The pathological diagnosis of the surgical piece was a peliosis hepatis.


Asunto(s)
Peliosis Hepática/diagnóstico , Diagnóstico Diferencial , Femenino , Hiperplasia Nodular Focal/diagnóstico , Humanos , Neoplasias Hepáticas/diagnóstico , Imagen por Resonancia Magnética , Persona de Mediana Edad , Tomografía Computarizada por Rayos X , Ultrasonografía Doppler en Color
11.
Rev. chil. cir ; 58(6): 420-430, dic. 2006. tab, graf
Artículo en Español | LILACS | ID: lil-455705

RESUMEN

El cáncer gástrico constituye en Chile la primera causa de muerte por cáncer en el hombre y la resección quirúrgica el único tratamiento que puede revertir el curso de la enfermedad. De un total de 195 pacientes operados de cáncer gástrico entre los años 1992 y 2001, se seleccionaron en un trabajo prospectivo los 108 casos sometidos a gastrectomía total con linfadenectomía D2 y resección R0, con los objetivos de evaluar la morbimortalidad postoperatoria, la sobrevida a cinco años y los factores pronósticos asociados. La mortalidad postoperatoria fue de un 0,9 por ciento y las complicaciones se presentaron en el 17,5 por ciento (fístulas 5,5 por ciento y abscesos subfrénicos 4,6 por ciento). La sobrevida global a 1 año fue 87,6 por ciento, a 3 años 61,1 por ciento y a 5 años 48,9 por ciento; para los cánceres precoces la sobrevida a cinco años fue 87,5 por ciento y para los avanzados 47 por ciento. En el análisis univariado los factores pronósticos significativos fueron el T, precoz versus avanzado y el compromiso linfonodal. En el análisis multivariado el único factor pronóstico significativo fue el compromiso linfonodal.


Asunto(s)
Masculino , Adulto , Humanos , Femenino , Persona de Mediana Edad , Gastrectomía/métodos , Escisión del Ganglio Linfático , Neoplasias Gástricas/cirugía , Neoplasias Gástricas/mortalidad , Análisis Multivariante , Epidemiología Descriptiva , Estadificación de Neoplasias , Ganglios Linfáticos/patología , Complicaciones Posoperatorias , Pronóstico , Estudios Prospectivos , Reoperación , Tasa de Supervivencia
12.
Bol. Hosp. San Juan de Dios ; 41(6): 353-62, nov.-dic. 1994. tab
Artículo en Español | LILACS | ID: lil-148373

RESUMEN

La pancreatitis aguda es una entidad frecuente en nuestro medio. La enfermedad biliar es la causa principal en el desencadenamiento de ella. La evolución de la pancreatitis aguda puede adquirir diferentes formas clínicas que se relacionan con el pronóstico. Se proponen factores pronósticos de la enfermedad tanto desde el punto de vista clínico, de laboratorio y de imagenología. Se analizan los tratamientos actuales y conductas terapéuticas


Asunto(s)
Humanos , Pancreatitis/diagnóstico , Amilasas/sangre , Diagnóstico Diferencial , Grupos Diagnósticos Relacionados , Enfermedades Pancreáticas/microbiología , Examen Físico/métodos , Infección Hospitalaria/diagnóstico , Lipasa/sangre , Pancreatitis/clasificación , Pancreatitis/complicaciones , Pancreatitis/terapia , Seudoquiste Pancreático/diagnóstico , Pruebas de Función Pancreática/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA